SRR5088836
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- TGF_BETA_SIGNALING+0.500
- COAGULATION+0.400
- PROTEIN_SECRETION+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- COMPLEMENT+0.300
- HEDGEHOG_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- MYC_TARGETS_V1-0.500
- OXIDATIVE_PHOSPHORYLATION-0.500
- PANCREAS_BETA_CELLS-0.500
- E2F_TARGETS-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- ADIPOGENESIS-0.300
- G2M_CHECKPOINT-0.300
- MTORC1_SIGNALING-0.300
- SPERMATOGENESIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088837 | — | — | 0.949 |
| 2 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.908 |
| 3 | TCGA-J2-8192-01A-11R-2241-07 | — | cohortA1 | 0.894 |
| 4 | TCGA-EW-A1J2-01A-21R-A13Q-07 | — | A | 0.893 |
| 5 | TCGA-85-6175-01A-11R-1820-07 | — | cohortSQ1 | 0.871 |
| 6 | TCGA-44-6774-01A-21R-1858-07 | — | cohortA1 | 0.869 |
| 7 | TCGA-AR-A24O-01A-11R-A169-07 | — | A | 0.868 |
| 8 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.858 |
| 9 | TCGA-77-8008-01A-21R-2187-07 | — | cohortSQ1 | 0.853 |
| 10 | TCGA-BH-A1EO-01A-11R-A137-07 | — | A | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |